TScan Therapeutics, Inc. (TCRX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, TScan Therapeutics, Inc. reported revenue of $10.32M, up 266.7% from the prior year. The company ran a net loss, with a net margin of -1256.8%. It held $228.79M in total assets against $105.67M in total liabilities.
Key ratios (FY2025)
-1315.4%
Operating margin
-1256.8%
Net margin
-105.4%
Return on equity
+266.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $10.32M | $2.82M | $21.05M | $13.54M | $10.14M | $1.08M | — |
| Operating Income | -$135.81M | -$134.82M | -$93.46M | -$66.64M | -$48.64M | -$26.23M | — |
| Net Income | -$129.77M | -$127.50M | -$89.22M | -$66.22M | -$48.62M | -$26.13M | — |
| EPS (Diluted) | $-1.00 | $-1.14 | $-1.36 | $-2.75 | $-4.17 | — | — |
| Total Assets | $228.79M | $371.12M | $272.15M | $199.09M | $188.11M | $49.74M | — |
| Total Liabilities | $105.67M | $130.15M | $121.28M | $99.66M | $27.33M | $32.52M | — |
| Shareholders' Equity | $123.12M | $240.97M | $150.87M | $99.43M | $160.78M | -$42.46M | -$17.14M |
| Cash & Equivalents | $152.41M | $178.69M | $133.36M | $120.03M | $161.41M | $34.79M | — |
| Operating Cash Flow | -$135.32M | -$110.82M | -$61.36M | -$66.50M | -$48.68M | -$3.02M | — |
| Capital Expenditures | $4.41M | $3.83M | $3.15M | $4.22M | $9.94M | $4.24M | — |
| Shares Outstanding | 129.78M | 111.99M | 65.60M | 24.05M | 11.66M | — | — |